Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs UnitedHealth Group Inc (UNH) Price & Performance

Davita IncTrade
UnitedHealth Group IncTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs UnitedHealth Group Inc — how do they compare? Davita Inc trades at $180.81 (market cap $11.38B), while UnitedHealth Group Inc trades at $406.32 (market cap $361.00B). The key difference: UnitedHealth Group Inc is far larger — about 31.7× Davita Inc's market cap, and UnitedHealth Group Inc pays a 2.31% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAUNH
Market Cap
$11.38B$361.00B
Sector
HealthHealth
52-Week High
$240.96$436.35
52-Week Low
$103.87$259.02
Enterprise Value
$24.10B$402.86B
Dividend Yield
2.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.

The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.

UnitedHealth Group Inc

UnitedHealth Group (UNH) trades at $402.19, down 1.6% with bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats with Q1 2026 EPS of $7.23 beating estimates by 12%. Revenue grew to $447.57 billion in 2025, though net margins compressed to 2.69%. Analyst consensus remains strongly bullish with 83% buy ratings and a $476.50 price target representing 18% upside potential.

UNH presents a compelling long-term investment opportunity driven by aging demographics and healthcare digitization, but faces near-term headwinds from regulatory scrutiny and margin pressure. The stock's current valuation at 25.85x P/E appears reasonable given growth prospects, though investors should monitor legal challenges and Medicare reimbursement trends that could impact profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About UnitedHealth Group Inc

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Read more on UNH